Get the latest news, insights, and market updates on IMUX (Immunic, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at... Feb 17, 2026 - $IMUX
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously disclosed private placement financing. Feb 17, 2026 - $IMUX
A Look At Immunic (IMUX) Valuation After Oversubscribed Funding And Leadership Changes
Immunic (IMUX) has moved into the spotlight after an oversubscribed private placement of up to US$400 million, paired with a CEO transition plan and board reshuffle related to its multiple sclerosis programs. See our latest analysis for Immunic. Investors appear to be reacting to the funding and leadership reset, with a 30 day share price return of 47.7% and a year to date share price return of 56.5%. However, the 1 year total shareholder return is still an 8.8% decline and the 5 year total... Feb 16, 2026 - $IMUX
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up
In February 2026, Immunic, Inc. announced an oversubscribed private placement of pre-funded and common warrants expected to raise up to US$400,000,000, alongside plans to complete late-stage multiple sclerosis trials, initiate a new phase 3 program in primary progressive multiple sclerosis, and prepare for potential commercialization of vidofludimus calcium. At the same time, the company outlined a leadership reshaping, elevating Simona Skerjanec to interim Chairperson, launching a search... Feb 15, 2026 - $IMUX
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline. Shares jumped nearly 28% on Friday... Feb 13, 2026 - $IMUX
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement with gross proceeds of up to USD 400 million priced at the market under Nasdaq rules. The financing was led by existing investor BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMe Feb 13, 2026 - $IMUX
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the latest data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company’s Phase 2 CALLIPER trial in progressive multiple sclerosis (MS). The discussion centered on two posters shared at the conference: one focusing on MRI outcomes and the other exploring EBV (Epstein-Barr Virus) reactivation. Muehler explained that vidofludimus calcium demonstrated reductions in gadolinium-enhancing and T2 lesions as well as slowly expanding lesions (SELs) - indicators of acute and chronic inflammation in MS, respectively. He outlined how MRI scans detected fewer SELs in treated patients, providing early clinical signs that vidofludimus calcium could address both peripheral and central nervous system inflammation in progressive MS. “These data from the CALLIPER trial really show for the first time that there's also clinical evidence that vidofludimus calcium is causing a statistically significant reduction in EBV reactivation with treatment over time as compared to placebo,” said Muehler. The EBV-related findings were particularly important, as mounting evidence suggests the virus is a necessary condition for MS. The company measured T-cell receptor repertoires and found a clear drop in EBV antigens among patients treated with vidofludimus calcium, suggesting reduced reactivation activity. Looking ahead, Muehler pointed to 2026 as a potential pivotal year, with the company expecting readouts from its two phase 3 trials in relapsing MS involving over 2,000 patients. These results are expected to inform regulatory submissions and could bring Immunic’s treatment closer to market. Visit Proactive's YouTube channel for more interviews, and don't forget to give this video a like, subscribe to our channel, and enable notifications so you never miss an update. #ImmunicInc #MSResearch #ProgressiveMS #VidofludimusCalcium #EBV #MultipleSclerosis #BiotechNews #ClinicalTrials #MSAwareness #MRIResearch #Neuroscience #PharmaInnovation #SELlesions #Phase2Trial #MSInflammation Feb 10, 2026 - $IMUX
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10%
Immunic, Inc. (NASDAQ:IMUX) is one of the stocks under $1 that will explode. Immunic, Inc. (NASDAQ:IMUX) has recently demonstrated strong share price momentum, with its shares up 24.10% in the past five days as of the market open on January 9, 2026. Amid the share price surge, the company’s management reviewed 2025 performance and outlined […] Jan 12, 2026 - $IMUX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple